FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4380084558> ?p ?o ?g. }

• W4380084558 endingPage "525" @default.
• W4380084558 startingPage "524" @default.
• W4380084558 abstract "Introduction: Autologous CD30.CAR-T therapy has demonstrated promising antitumor activity with favorable safety profile in relapsed or refractory (r/r) classical Hodgkin Lymphoma (cHL) patients. Hodgkin Reed-Sternberg cells, the target of CD30.CAR-T, frequently overexpress PD-L1/PD-L2. Checkpoint inhibitors (CPI) of PD-1, including nivolumab (nivo), have shown effective and safe in r/r cHL. Pre-clinical studies suggest that combination of CPI and CAR-T therapy could enhance the survival of CAR-T cells and promote tumor cell death. Methods: A single-arm, phase 1b, multicenter study (NCT# 05352828) is being conducted to evaluate safety and antitumor activity of combined CD30.CAR-T and nivo in r/r cHL patients after frontline therapy failure, with 15 patients to be enrolled. Patients are treated with 2 cycles of nivo, followed by a single infusion of CD30.CAR-T preceded by lymphodepletion (LD) chemotherapy. An additional 2 cycles of nivo are then given, followed by response assessment by PET/CT per Lugano 2014 criteria. Patients without progressive disease may undergo either autologous stem cell transplant or continue nivo up to 6 additional cycles per physician and patient preference. Results: A total of 15 patients were enrolled (Table 1). To date, all patients were treated with at least 2 cycles of nivo, and 10 patients treated with CD30.CAR-T (median dose: 2.4 [range: 2.0–2.7] ×108 cells/m2). Combined therapy was well tolerated. 86.7% (13/15) patients experienced at least one AE with 46.7% patients having grade ≥3 AEs which were hematologic toxicities mainly due to LD chemotherapy. Two patients had cytokine release syndrome (Grade 1), which resolved without use of steroid or tocilizumab. No neurotoxicity was observed. Among 5 patients treated with CD30.CAR-T and 4 cycles of nivo, there were 4 complete response (CR) and one stable disease (SD). ctDNA-MRD was assessed with PhasED-Seq (Foresight Diagnostics) in 3 patients where samples were available to date, all with radiographic CR. All 3 patients (100%) had undetectable ctDNA-MRD at this timepoint, demonstrating deep molecular response. Conclusion: Preliminary data demonstrated favorable safety profile and promising anti-tumor responses of CD30.CAR-T combined with nivo in r/r cHL patients after failure of frontline therapy. Evaluation of 15 patients enrolled is ongoing, and the clinical and ctDNA-MRD data will be presented at the meeting. The research was funded by: Tessa Therapeutics Keywords: Cellular therapies, Hodgkin lymphoma Conflicts of interests pertinent to the abstract. S. Ahmed Consultant or advisory role: Chimagen, Tessa Therapeutics, Myeloid Therapeutics, ADC therapeutics, KITE/Gilead Research funding: Seattle Genetics, Merck, Xencor, Chimagen, Tessa Therapeutic M. Mei Honoraria: Novartis Research funding: BMS Other remuneration: Speaker Bureau: Morphosys, SeaGen D. M. Kurtz Consultant or advisory role: Foresight Diagnostics, Genentech, Roche, Adaptive Biotechnologies Stock ownership: Foresight Diagnostics A. Beitinjaneh Consultant or advisory role: Kite/Gilead N. S. Grover Consultant or advisory role: Novartis, Tessa Therapeutics, ADC Therapeutics, Kite, Caribou Research funding: Genentech C. A. Ramos Consultant or advisory role: Tessa Therapeutics, Athenex Therapeutics, Genentech, Novartis, CRISPR Therapeutics Research funding: Tessa Therapeutics, Athenex Therapeutics Other remuneration: Royalties & Patents: Tessa Therapeutics, J. J. Chabon Employment or leadership position: Foresight Diagnostics Stock ownership: Foresight Diagnostics A. Schultz Employment or leadership position: Foresight Diagnostics C. Ding Employment or leadership position: Tessa Therapeutics A. Myo Employment or leadership position: Tessa Therapeutics A. A. Alizadeh Consultant or advisory role: Foresight Diagnostics, Cibermed, Adaptive Biotechnologies, Gilead, Roche, BMS, Genentech, Karyopharm Stock ownership: Foresight Diagnostics, Cibermed, Gilead, Syncopation Research funding: BMS I. D. Horak Employment or leadership position: Tessa Therapeutics H. E. Heslop Consultant or advisory role: Ankarys, Fresh Wind Biotechnologies, Gilead Biosciences, GlaxoSmithKline, Millenium, Novartis, Tessa Therapeutics Stock ownership: Allovir, Marker Therapeutics, Coregen, Fresh Wind Biotechnologies Research funding: Kuur Therapeutics, Tessa Therapeutics" @default.
• W4380084558 created "2023-06-10" @default.
• W4380084558 creator A5004593255 @default.
• W4380084558 creator A5007420876 @default.
• W4380084558 creator A5009486107 @default.
• W4380084558 creator A5016426367 @default.
• W4380084558 creator A5021029688 @default.
• W4380084558 creator A5036591050 @default.
• W4380084558 creator A5038261300 @default.
• W4380084558 creator A5039574726 @default.
• W4380084558 creator A5062966348 @default.
• W4380084558 creator A5068037005 @default.
• W4380084558 creator A5068290727 @default.
• W4380084558 creator A5070934428 @default.
• W4380084558 creator A5076624501 @default.
• W4380084558 date "2023-06-01" @default.
• W4380084558 modified "2023-10-12" @default.
• W4380084558 title "Combined autologous CD30.CAR‐T cells and nivolumab in patients with relapsed or refractory classical Hodgkin Lymphoma after failure of frontline therapy (ACTION study)" @default.
• W4380084558 doi "https://doi.org/10.1002/hon.3164_388" @default.
• W4380084558 hasPublicationYear "2023" @default.
• W4380084558 type Work @default.
• W4380084558 citedByCount "0" @default.
• W4380084558 crossrefType "journal-article" @default.
• W4380084558 hasAuthorship W4380084558A5004593255 @default.
• W4380084558 hasAuthorship W4380084558A5007420876 @default.
• W4380084558 hasAuthorship W4380084558A5009486107 @default.
• W4380084558 hasAuthorship W4380084558A5016426367 @default.
• W4380084558 hasAuthorship W4380084558A5021029688 @default.
• W4380084558 hasAuthorship W4380084558A5036591050 @default.
• W4380084558 hasAuthorship W4380084558A5038261300 @default.
• W4380084558 hasAuthorship W4380084558A5039574726 @default.
• W4380084558 hasAuthorship W4380084558A5062966348 @default.
• W4380084558 hasAuthorship W4380084558A5068037005 @default.
• W4380084558 hasAuthorship W4380084558A5068290727 @default.
• W4380084558 hasAuthorship W4380084558A5070934428 @default.
• W4380084558 hasAuthorship W4380084558A5076624501 @default.
• W4380084558 hasBestOaLocation W43800845581 @default.
• W4380084558 hasConcept C121332964 @default.
• W4380084558 hasConcept C121608353 @default.
• W4380084558 hasConcept C126322002 @default.
• W4380084558 hasConcept C141071460 @default.
• W4380084558 hasConcept C142424586 @default.
• W4380084558 hasConcept C143998085 @default.
• W4380084558 hasConcept C2777701055 @default.
• W4380084558 hasConcept C2779338263 @default.
• W4380084558 hasConcept C2780030458 @default.
• W4380084558 hasConcept C70905583 @default.
• W4380084558 hasConcept C71924100 @default.
• W4380084558 hasConcept C87355193 @default.
• W4380084558 hasConceptScore W4380084558C121332964 @default.
• W4380084558 hasConceptScore W4380084558C121608353 @default.
• W4380084558 hasConceptScore W4380084558C126322002 @default.
• W4380084558 hasConceptScore W4380084558C141071460 @default.
• W4380084558 hasConceptScore W4380084558C142424586 @default.
• W4380084558 hasConceptScore W4380084558C143998085 @default.
• W4380084558 hasConceptScore W4380084558C2777701055 @default.
• W4380084558 hasConceptScore W4380084558C2779338263 @default.
• W4380084558 hasConceptScore W4380084558C2780030458 @default.
• W4380084558 hasConceptScore W4380084558C70905583 @default.
• W4380084558 hasConceptScore W4380084558C71924100 @default.
• W4380084558 hasConceptScore W4380084558C87355193 @default.
• W4380084558 hasIssue "S2" @default.
• W4380084558 hasLocation W43800845581 @default.
• W4380084558 hasOpenAccess W4380084558 @default.
• W4380084558 hasPrimaryLocation W43800845581 @default.
• W4380084558 hasRelatedWork W2353137601 @default.
• W4380084558 hasRelatedWork W2478002927 @default.
• W4380084558 hasRelatedWork W2800160190 @default.
• W4380084558 hasRelatedWork W2890849069 @default.
• W4380084558 hasRelatedWork W2898986397 @default.
• W4380084558 hasRelatedWork W2914827752 @default.
• W4380084558 hasRelatedWork W2947988614 @default.
• W4380084558 hasRelatedWork W2976744492 @default.
• W4380084558 hasRelatedWork W2981652925 @default.
• W4380084558 hasRelatedWork W3021851930 @default.
• W4380084558 hasVolume "41" @default.
• W4380084558 isParatext "false" @default.
• W4380084558 isRetracted "false" @default.
• W4380084558 workType "article" @default.